



PATENT  
Attorney Docket No. 60730.000002

RECEIVED  
MAR 14 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: )  
Nils BRÜNNER *et al.* )  
Application No.: 10/030,971 ) Group Art Unit: 1615  
Filed: January 15, 2002 ) Examiner: Unassigned

For: COMPOSITION HAVING STEROIDAL ESTROGEN EFFECT WITHOUT  
INCREASING THE RISK OF BREAST CANCER

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Director of the United States  
Patent and Trademark Office  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 and as a follow-up to the Information Disclosure Statement ("IDS") filed May 16, 2002, Applicants hereby submit the attached Form PTO-1449 listing cited references and request consideration thereof. Copies of the listed references are enclosed.

Applicants submit English-language equivalents, translations or abstracts of six (6) German language documents that were filed in the May 16, 2002 IDS, i.e., the references C, R, T, W, X and Y identified on the Form PTO-1449. Please note that a U.S. patent equivalent is being submitted for document C, English abstracts are being submitted for documents R, T, W, and X, and a full translation is being submitted for document Y.




21967

PATENT TRADEMARK OFFICE

This Second Supplemental IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Second Supplemental Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS



Stanislaus Aksman

Registration No. 28,562

Date: March 12, 2003

1900 K Street, N.W., Suite 1200  
Washington, D.C. 20006-1109  
Ph. (202) 955-1500  
Fax (202) 778-2201  
SA/cmt

